Chapter 7
A small-molecule drug is made, tested, and released as a stable chemical entity. A regenerative product is different because the product is a population of living cells, or a construct built from them. It cannot be terminally sterilized, and it cannot be filtered to remove a contaminant without losing the therapy. Its identity, purity, and potency depend on a manufacturing history that begins with a donor or a banked cell line and ends at the bedside. Consequently, no single rulebook governs it. WIA-BIO-020 Phase 4 treats the specification as one node in an ecosystem of pharmacopoeial methods, cleanroom standards, donor-eligibility rules, and regional product regulations.
The first three phases of the standard define the data envelopes, the HTTPS surface that exposes them, and the protocol exchanges that cross trust boundaries. Phase 4 asks a different question: when a record produced under this standard reaches an inspector, a regulator, or an ethics committee, does it line up with what that reader is obliged to check? The standard answers by naming the external instruments that matter and by describing the integration "envelopes" that tie them to a lot, a facility, or a trial. The core instruments are:
The specification states plainly that its cross-walk of these instruments is informative. Implementers must obtain the authoritative text from the issuing body, because pharmacopoeial chapters and regulations are revised on their own schedules and a standard cannot freeze them.
The remaining sections follow the lifecycle of a regenerative product: how it is classified and filed (7.2), how it is made (7.3), how a lot is released (7.4), and how it is studied and monitored in patients (7.5).
The first regulatory question for any cell-based product is which regime applies. The answer determines the evidence required, the timeline, and the review body. WIA-BIO-020 records the classification decision rather than leaving it implicit in a filing.
United States. The HCT/P decision tree separates two outcomes. A product that is minimally manipulated and intended for homologous use falls under Section 361 and carries a reduced regulatory burden. Anything else falls under Section 351 and requires a full Biologics License Application. The FDA guidance on minimal manipulation and homologous use (2020) is the interpretive reference.
A product that must go the 351 route can seek Regenerative Medicine Advanced Therapy (RMAT) designation. The specification lists three criteria:
RMAT sits alongside the existing expedited programs: Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval. A submission package should contain pre-IND meeting documentation, a CMC (Chemistry, Manufacturing, Controls) section, nonclinical studies covering toxicology and biodistribution, and clinical protocols across Phases I to III.
European Union. EC Regulation 1394/2007 defines four ATMP categories: gene therapy medicinal products, somatic cell therapy medicinal products, tissue-engineered products, and combined ATMPs. The requirements are quality under GMP, preclinical safety, clinical efficacy, a risk management plan, and a pharmacovigilance system. The EMA Guideline EMA/CAT/600280/2010 gives the risk-based approach for cell-based ATMPs, and filing runs through the centralized procedure.
The specification also names three further regimes: the KFDA cell-therapy framework, the PMDA Sakigake conditional-approval route in Japan, and the NMPA cell-therapy classification in China. The integration envelope records, for each jurisdiction, the filing strategy, the consultation history (pre-IND, Type B/C/D meetings, or Pre-Submission), and the post-market surveillance commitments.
| Jurisdiction | Governing instrument | What the integration record captures |
|---|---|---|
| United States | 21 CFR 1271; Section 361 / 351; RMAT | Pathway chosen (361 or 351), designation status, pre-IND history |
| European Union | EC Regulation 1394/2007 | ATMP category, centralized-procedure status, risk management plan |
| Korea | KFDA cell-therapy framework | Per-jurisdiction filing strategy |
| Japan | PMDA Sakigake conditional approval | Conditional-approval status, surveillance commitments |
| China | NMPA cell-therapy classification | Classification outcome, consultation history |
Keeping this as structured data matters because multinational programs rarely move in lockstep. A product may be a Section 351 biologic in one market and an ATMP in another. The consultation record explains why each regulator received the evidence it did, and that explanation is what a reviewer asks for when two filings seem to disagree.
Aseptic manufacturing is the central control for living products, because no terminal sterilization step exists. The specification sets out the critical parameters for the manufacturing environment:
| Parameter | Specified value |
|---|---|
| Clean room | ISO Class 5 (Class 100) |
| Air quality | <3,520 particles ≥0.5 μm per m³ |
| Temperature | 20–24 °C |
| Humidity | 30–60% RH |
| Sterility testing | <1 CFU per sample |
The Phase 4 integration text places these values inside the wider classification scheme of ISO 14644-1, -2, and -7. EU GMP Annex 1 expects a Grade A laminar-flow zone within a Grade B background. US FDA aseptic-processing guidance expects ISO 5 within an ISO 7 surround. The two models are not identical, so a facility serving both markets must show that it satisfies the stricter reading of each. The standard asks the integration record to capture the classification envelope itself rather than a bare "ISO 5" label.
Classification alone does not show that a room stays clean. The record therefore also covers the following:
The documentation set is anchored by the Master Cell Bank (MCB) characterization, batch production records, quality-control results, and chain-of-custody documentation. Chain of custody is more than administrative for an autologous product. If the cells of one patient are returned to another, the error cannot be reversed. For banked material the specification points to ISO 20387 for biobanking general requirements and to ICH Q5D for the characterization of cell substrates, which supports the genetic-stability check described in 7.4.
Donor eligibility sits upstream of all of this. In the United States it is governed by 21 CFR 1271 Subpart C, and in the European Union by Directives 2004/23/EC and 2006/17/EC. A well-controlled cleanroom cannot compensate for starting material that was never eligible, so the integration record links each lot to its donor-eligibility determination.
Release criteria turn the question "is this lot safe and active enough to give?" into a pass/fail decision. The specification defines the following acceptance criteria:
| Test | Acceptance criterion |
|---|---|
| Sterility | No growth (14 days) |
| Endotoxin | <5 EU/kg body weight |
| Mycoplasma | Negative |
| Viability | >70% |
| Identity | Marker expression >90% |
| Purity | Contaminating cells <5% |
| Potency | Functional assay specific to the product |
| Karyotype | Normal (if applicable) |
Two features of this table shape how a lot is actually handled. First, the sterility criterion is a 14-day culture. For a fresh product with a short shelf life, the result may arrive after the patient has already been treated. Programs typically pair the compendial test with rapid in-process checks, and they must document what happens if a late positive appears. The standard does not prescribe that procedure. It does require the release record to show which results were available at the time of release. Second, potency is deliberately "functional assay specific." A cell therapy has no universal potency test, because the relevant biology differs for a cartilage construct, a cardiac cell product, and a retinal graft. USP <1046> frames the expectation, but the assay itself is defined per product.
The cross-walk maps each concern to its external method. The main rows are:
| Concern | Instrument |
|---|---|
| Sterility, finished product | USP <71> |
| Endotoxin | USP <85> and EU Pharmacopoeia 2.6.14 |
| Mycoplasma | USP <63> and EU Pharmacopoeia 2.6.7 |
| Potency | USP <1046> |
| Identity by STR profiling | ANSI/ATCC ASN-0002 |
| Genetic stability | ISO 20387 and ICH Q5D |
| Viral safety of cell-line-derived products | ICH Q5A(R1) |
| Biological evaluation of devices and scaffolds | ISO 10993 |
STR profiling answers a problem that has damaged real research programs: cell lines that are misidentified or cross-contaminated. Identity by marker expression shows that the cells look like the intended type, but STR profiling shows that they are the same cells that were banked. The ISO 10993 entry matters wherever a scaffold from the tissue-engineering chapters, such as collagen, PLGA, PCL, or alginate, becomes part of a combined product. In that case the device-side biological evaluation and the cell-side release testing both apply to the same lot.
The following plain-text checklist shows how a release reviewer might read a lot against these criteria. It is a working aid built from the table above, not a wire format defined by the standard.
LOT RELEASE REVIEW (illustrative checklist)
[ ] Donor eligibility determination on file (21 CFR 1271 Subpart C / 2004/23/EC)
[ ] MCB characterization referenced
[ ] Sterility ........ no growth at 14 days (USP <71>)
[ ] Endotoxin ........ <5 EU/kg body weight (USP <85>)
[ ] Mycoplasma ....... negative (USP <63>)
[ ] Viability ........ >70%
[ ] Identity ......... marker expression >90%; STR match (ASN-0002)
[ ] Purity ........... contaminating cells <5%
[ ] Potency .......... product-specific functional assay passed
[ ] Karyotype ........ normal, where applicable
[ ] Environmental monitoring reviewed for the batch window
[ ] Chain of custody intact; certificate of analysis issuedManufacturing and release determine whether a product may be given. Clinical-trial integration determines what is learned once it is. The specification treats the trial as a bundle of external obligations that must stay consistent with each other:
Regenerative trials raise follow-up questions that conventional drug trials seldom do. A cell product may engraft and persist for years, so safety monitoring must extend well beyond the dosing window. A gene-edited or iPSC-derived product adds long-term concerns about genetic stability and unintended cell behavior. Tying trial records to the manufacturing lot lets a late adverse event be traced to a specific batch, its release data, and its donor.
The standard's outlook lists several active research tracks. They are organoid-based personalised disease modelling and screening, and autologous iPSC-derived therapies for Parkinson's disease, type 1 diabetes, retinal degeneration, sickle-cell disease, and severe combined immunodeficiency. They also include allogeneic universal-donor iPSC banks with HLA-engineered immune evasion, and in-situ programming through CAR-T-engineered cells for non-oncology indications. The list further covers CRISPR-Cas9 stem-cell therapies using base or prime editing, and bioprinted vascularized organ constructs. Each track stresses a different part of the framework above. Universal-donor banks raise donor-eligibility and MCB questions at larger scale, gene-edited cells raise genetic-stability and viral-safety questions, and bioprinted organs raise combined-product classification. The standard's roadmap interface (POST /standards/v1/proposals) tracks proposals as they pass through committee voting.
Within the 1.x line, existing envelopes, endpoints, and protocol exchanges remain reachable, and hosts may add optional fields but not remove existing ones. Breaking changes require a major version with a 12-month deprecation window. A reference container and conformance suite let integrators exercise these behaviours against mock data before connecting real backends.
Summary. This chapter has treated Phase 4 as the point where the specification meets the rules that govern living therapeutic products. Classification decides which regulator and which evidence apply: HCT/P Section 361 or 351 in the United States, one of four ATMP categories in Europe, and the equivalent regimes in Korea, Japan, and China. RMAT and the other expedited programs shorten the path for serious conditions, but they do not relax CMC or safety expectations. GMP and ISO 14644 define the aseptic environment, while the batch record, environmental monitoring, and chain of custody show that the environment was held. Release criteria, mapped to USP methods, STR profiling, and ICH guidance, convert that evidence into a decision, and trial registration, ethics oversight, and adverse-event reporting extend the same traceability into patients. The next chapter moves from these external obligations to the day-to-day operation of a deployment, including how the contract is stood up, verified, and maintained over time.